Dare Bioscience, Inc.
DARE Nasdaq
SEC CIK 1401914
Follow Dare Bioscience
Weekly email: filings, results
Revenue, last quarter
$47.6K
+2005.6% vs same quarter last year
Net income
−$3.2M
+11.4% vs same quarter last year
EPS, diluted
−$0.18
+35.7% vs same quarter last year
Operating cash flow
−$6.8M
−1084.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1M | −$13.4M |
| FY24 | $9.8K | −$4.1M |
| FY23 | $2.8M | −$30.2M |
| FY22 | $10M | −$30.9M |
| FY21 | $0 | −$38.7M |
| FY20 | - | −$27.4M |
| FY19 | - | −$14.3M |
| FY18 | - | −$16.7M |
| FY17 | - | - |
| FY16 | $766K | −$672.7K |
| FY15 | - | −$39.6M |
| FY14 | $80K | −$23.3M |
| FY13 | $6K | −$17.1M |
| FY12 | $625K | −$22.1M |
| FY11 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1315.5% | −1300.7% |
| FY24 | −239692.2% | −41394.1% |
| FY23 | −1101.9% | −1074.1% |
| FY22 | −313.9% | −309.5% |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | −82.3% | −87.8% |
| FY15 | - | - |
| FY14 | - | −29177.5% |
| FY13 | - | −285716.7% |
| FY12 | - | −3536.2% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$10.3M |
| FY24 | $4.9M |
| FY23 | −$39.5M |
| FY22 | −$18.2M |
| FY21 | −$28.8M |
| FY20 | −$25.3M |
| FY19 | −$13.3M |
| FY18 | −$10.3M |
| FY17 | −$2.5M |
| FY16 | −$907.3K |
| FY15 | −$32.2M |
| FY14 | −$19.3M |
| FY13 | −$16.6M |
| FY12 | −$21.2M |
| FY11 | - |
- Dare Bioscience
- Healthcare median
Show the numbers
| Year | Dare Bioscience | Healthcare median |
|---|---|---|
| FY25 | −1300.7% | −30.6% |
| FY24 | −41394.1% | −47% |
| FY23 | −1074.1% | −58% |
| FY22 | −309.5% | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | −87.8% | −36% |
| FY15 | - | −38.4% |
| FY14 | −29177.5% | −35.5% |
| FY13 | −285716.7% | −37.1% |
| FY12 | −3536.2% | −29.1% |
| FY11 | - | −27.9% |